Abstract

Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterized by isolated thrombocytopenia due to accelerated platelet destruction and impaired platelet production. Diagnosis of ITP is still challenging because ITP has been diagnosed by exclusion. Exclusion of thrombocytopenia due to bone marrow failure is especially important in Japan because of high prevalence of aplastic anemia compared to Western countries. Hence, we propose a new diagnostic criteria involving the measurement of plasma thrombopoietin (TPO) levels and percentage of immature platelet fraction (RP% or IPF%); 1) isolated thrombocytopenia with no morphological evidence of dysplasia in any blood cell type in a blood smear, 2) normal or slightly increased plasma TPO level (< cutoff), 3) elevated RP% or IPF% (> upper limit of normal), and 4) absence of other conditions that potentially cause thrombocytopenia including secondary ITP. A diagnosis of ITP is made if conditions 1-4 are all met. Cases in which criterion 2 or 3 is not met or unavailable are defined as “possible ITP,” and diagnosis of ITP can be made mainly by typical clinical course. These new criteria enable us to clearly differentiate ITP from aplastic anemia and other forms of hypoplastic thrombocytopenia and can be highly useful in clinical practice for avoiding unnecessary bone marrow examination as well as for appropriate selection of treatments.

Details

Title
Reference guide for the diagnosis of adult primary immune thrombocytopenia, 2023 edition
Author
Kashiwagi, Hirokazu 1   VIAFID ORCID Logo  ; Kuwana, Masataka 2 ; Murata, Mitsuru 3 ; Shimada, Naoki 4 ; Takafuta, Toshiro 5 ; Yamanouchi, Jun 6 ; Kato, Hisashi 7 ; Hato, Takaaki 8 ; Tomiyama, Yoshiaki 7 

 Osaka University Hospital, Department of Blood Transfusion, Suita, Japan (GRID:grid.412398.5) (ISNI:0000 0004 0403 4283) 
 Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan (GRID:grid.410821.e) (ISNI:0000 0001 2173 8328) 
 International University of Health and Welfare, Center for Clinical Medical Research, Ohtawara, Tochigi, Japan (GRID:grid.411731.1) (ISNI:0000 0004 0531 3030) 
 International University of Health and Welfare, Center for Basic Medical Research, Ohtawara, Tochigi, Japan (GRID:grid.411731.1) (ISNI:0000 0004 0531 3030) 
 Hiroshima City Funairi Citizens Hospital, Department of Internal Medicine, Hiroshima, Hiroshima, Japan (GRID:grid.411731.1) 
 Ehime University Hospital, Division of Blood Transfusion and Cell Therapy, Toon, Ehime, Japan (GRID:grid.452478.8) (ISNI:0000 0004 0621 7227) 
 Osaka University, Department of Hematology and Oncology, Graduate School of Medicine, Suita, Osaka, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971) 
 Japanese Red Cross Ehime Blood Center, Matsuyama, Ehime, Japan (GRID:grid.410775.0) (ISNI:0000 0004 1762 2623) 
Pages
1-13
Publication year
2024
Publication date
Jan 2024
Publisher
Springer Nature B.V.
ISSN
09255710
e-ISSN
18653774
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2910730335
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.